180 related articles for article (PubMed ID: 21559963)
1. Binding of BIS like and other ligands with the GSK-3β kinase: a combined docking and MM-PBSA study.
Jena NR
J Mol Model; 2012 Feb; 18(2):631-44. PubMed ID: 21559963
[TBL] [Abstract][Full Text] [Related]
2. Structure-based approaches in the design of GSK-3 selective inhibitors.
Patel DS; Dessalew N; Iqbal P; Bharatam PV
Curr Protein Pept Sci; 2007 Aug; 8(4):352-64. PubMed ID: 17696868
[TBL] [Abstract][Full Text] [Related]
3. A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.
Liu Y; Agrawal NJ; Radhakrishnan R
J Mol Model; 2013 Jan; 19(1):371-82. PubMed ID: 22926267
[TBL] [Abstract][Full Text] [Related]
4. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
5. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.
Kumar A; Srivastava G; Negi AS; Sharma A
J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523
[TBL] [Abstract][Full Text] [Related]
6. Allosteric regulation of glycogen synthase kinase 3β: a theoretical study.
Buch I; Fishelovitch D; London N; Raveh B; Wolfson HJ; Nussinov R
Biochemistry; 2010 Dec; 49(51):10890-901. PubMed ID: 21105670
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.
Kuo GH; Prouty C; DeAngelis A; Shen L; O'Neill DJ; Shah C; Connolly PJ; Murray WV; Conway BR; Cheung P; Westover L; Xu JZ; Look RA; Demarest KT; Emanuel S; Middleton SA; Jolliffe L; Beavers MP; Chen X
J Med Chem; 2003 Sep; 46(19):4021-31. PubMed ID: 12954055
[TBL] [Abstract][Full Text] [Related]
8. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
Gaisina IN; Gallier F; Ougolkov AV; Kim KH; Kurome T; Guo S; Holzle D; Luchini DN; Blond SY; Billadeau DD; Kozikowski AP
J Med Chem; 2009 Apr; 52(7):1853-63. PubMed ID: 19338355
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent and bioavailable GSK-3beta inhibitors.
Gong L; Hirschfeld D; Tan YC; Heather Hogg J; Peltz G; Avnur Z; Dunten P
Bioorg Med Chem Lett; 2010 Mar; 20(5):1693-6. PubMed ID: 20138512
[TBL] [Abstract][Full Text] [Related]
10. Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3.
Zhang HC; Boñaga LV; Ye H; Derian CK; Damiano BP; Maryanoff BE
Bioorg Med Chem Lett; 2007 May; 17(10):2863-8. PubMed ID: 17350261
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics study of the inhibitory effects of ChEMBL474807 on the enzymes GSK-3β and CDK-2.
Czeleń P; Szefler B
J Mol Model; 2015 Apr; 21(4):74. PubMed ID: 25754137
[TBL] [Abstract][Full Text] [Related]
12. Elucidating substrate and inhibitor binding sites on the surface of GSK-3β and the refinement of a competitive inhibitor.
Licht-Murava A; Plotkin B; Eisenstein M; Eldar-Finkelman H
J Mol Biol; 2011 Apr; 408(2):366-78. PubMed ID: 21354422
[TBL] [Abstract][Full Text] [Related]
13. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
Darshit BS; Balaji B; Rani P; Ramanathan M
J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
[TBL] [Abstract][Full Text] [Related]
14. Screening of
Chandel S; Singh R; Gautam A; Ravichandiran V
J Biomol Struct Dyn; 2022; 40(23):12827-12840. PubMed ID: 34569452
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel glycogen synthase kinase-3beta substrate-interacting residues suggests a common mechanism for substrate recognition.
Ilouz R; Kowalsman N; Eisenstein M; Eldar-Finkelman H
J Biol Chem; 2006 Oct; 281(41):30621-30. PubMed ID: 16893889
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
Ye Q; Xu G; Lv D; Cheng Z; Li J; Hu Y
Bioorg Med Chem; 2009 Jul; 17(13):4302-12. PubMed ID: 19481464
[TBL] [Abstract][Full Text] [Related]
17. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
18. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors.
Bertrand JA; Thieffine S; Vulpetti A; Cristiani C; Valsasina B; Knapp S; Kalisz HM; Flocco M
J Mol Biol; 2003 Oct; 333(2):393-407. PubMed ID: 14529625
[TBL] [Abstract][Full Text] [Related]
19. Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors.
Kim KH; Gaisina I; Gallier F; Holzle D; Blond SY; Mesecar A; Kozikowski AP
J Mol Model; 2009 Dec; 15(12):1463-79. PubMed ID: 19440740
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors.
Ye Q; Shen Y; Zhou Y; Lv D; Gao J; Li J; Hu Y
Eur J Med Chem; 2013 Oct; 68():361-71. PubMed ID: 23994329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
